Crystalline forms of tryosine kinase inhibitors and their salts
AssigneeVM Pharma LLC
InventorsJay Jie-Qiang Wu, Ling Wang
Life of this patent
Estimating the term…
Abstract
The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
Claims30
A crystalline compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, with the following structure:
An amorphous form of Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate.
A combination, comprising:
- a) a crystalline Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, with the following structure:
- or
- b) an amorphous form of Compound I:
- and
- one or more pharmaceutically acceptable excipients.
A solid or semi-solid dosage form, comprising:
- a) a crystalline Compound I, sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, with the following structure:
- or
- b) an amorphous form of Compound I;
- or
- c) a combination of the crystalline Compound I and the amorphous form of Compound I.
Dependencies are inferred from the claim text.